Novavax (NASDAQ:NVAX) had its target price boosted by HC Wainwright from $10.00 to $17.00 in a research report sent to investors on Wednesday, Briefing.com Automated Import reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

NVAX has been the subject of a number of other reports. Oppenheimer upped their target price on Novavax from $1.25 to $25.00 in a research report on Monday, May 13th. ValuEngine upgraded Novavax from a sell rating to a hold rating in a research report on Thursday, August 1st. Zacks Investment Research upgraded Novavax from a hold rating to a buy rating and set a $8.00 target price for the company in a research report on Thursday, May 16th. Cantor Fitzgerald restated a hold rating on shares of Novavax in a research report on Thursday, May 9th. Finally, Chardan Capital restated a neutral rating and issued a $7.00 target price on shares of Novavax in a research report on Friday, May 10th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the stock. Novavax has a consensus rating of Hold and a consensus target price of $40.70.

NVAX opened at $7.84 on Wednesday. Novavax has a 1-year low of $4.01 and a 1-year high of $51.60. The business has a 50 day moving average price of $4.82 and a two-hundred day moving average price of $3.17.

Novavax (NASDAQ:NVAX) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.08). The business had revenue of $3.36 million during the quarter, compared to analysts’ expectations of $3.53 million. During the same period last year, the business earned ($2.40) EPS. On average, analysts predict that Novavax will post -5.6 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Oppenheimer & Co. Inc. bought a new position in shares of Novavax in the first quarter valued at $40,000. Wedbush Securities Inc. increased its holdings in shares of Novavax by 102.1% in the first quarter. Wedbush Securities Inc. now owns 54,444 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 27,500 shares in the last quarter. DekaBank Deutsche Girozentrale increased its holdings in shares of Novavax by 21.8% in the first quarter. DekaBank Deutsche Girozentrale now owns 123,100 shares of the biopharmaceutical company’s stock valued at $185,000 after buying an additional 22,000 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Novavax by 3,799.2% in the first quarter. SG Americas Securities LLC now owns 435,107 shares of the biopharmaceutical company’s stock valued at $240,000 after buying an additional 423,948 shares in the last quarter. Finally, Creative Planning increased its holdings in shares of Novavax by 161.7% in the first quarter. Creative Planning now owns 513,324 shares of the biopharmaceutical company’s stock valued at $283,000 after buying an additional 317,204 shares in the last quarter.

Novavax Company Profile

Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.

Read More: How is Preferred Stock Different from Common Stock?

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.